SAN FRANCISCO and SUZHOU, China, Aug. 11, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,…
Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia
Share this article
More News
Analysts reset Broadcom stock price target
May 21, 2026
Lumentum Stock Analysis: Buy or Sell?
May 21, 2026